Skip to content
PIL Logo

Relvar Ellipta inhalation powder, pre-dispensed

Last Updated on eMC 31-May-2017 View document  | GlaxoSmithKline UK Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 31-May-2017 and displayed until Current

Reasons for adding or updating:

  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 6 - date of revision

Updated on 03-May-2017 and displayed until 31-May-2017

Reasons for adding or updating:

  • Change to section 4 - possible side effects
  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - date of revision

Updated on 08-Jul-2016 and displayed until 03-May-2017

Reasons for adding or updating:

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 22-Jan-2016 and displayed until 08-Jul-2016

Reasons for adding or updating:

  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 22-Dec-2015 and displayed until 22-Jan-2016

Reasons for adding or updating:

  • Change to section 4 - possible side effects
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 29-Sep-2015 and displayed until 22-Dec-2015

Reasons for adding or updating:

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 01-Jul-2015 and displayed until 29-Sep-2015

Reasons for adding or updating:

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 06-Jan-2015 and displayed until 01-Jul-2015

Reasons for adding or updating:

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 05-Jan-2015 and displayed until 06-Jan-2015

Reasons for adding or updating:

  • Change to section 4 - possible side effects

Updated on 09-Jun-2014 and displayed until 05-Jan-2015

Reasons for adding or updating:

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision

Updated on 08-Jan-2014 and displayed until 09-Jun-2014

Reasons for adding or updating:

  • New PIL for new product

Company contact details

GlaxoSmithKline UK

Company image
Address

Stockley Park West, Uxbridge, Middlesex, UB11 1BT

Fax

+44 (0)208 990 4328

Medical Information e-mail
Telephone

0800 221 441

E-mail
Customer Care direct line

0800 221 441

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

fluticasone furoate , vilanterol trifenatate

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue